Plasma osteopontin is an independent prognostic marker for head and neck cancers

Journal of Clinical Oncology

Volumn 24, Issue 33, 2006, Pages 5291-5297

  Petrik, David ^a   Lavori, Philip W ^a   Cao, Hongbin ^a   Zhu, Yonghua ^a   Wong, Priscilla ^a   Christofferson, Erin ^a   Kaplan, Michael J ^a   Pinto, Harlan A ^a   Sutphin, Patrick ^a   Koong, Albert C ^a   Giaccia, Amato J ^a   Le, Quynh Thu ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; OSTEOPONTIN; TUMOR MARKER;

ADULT; ARTICLE; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; NECK DISSECTION; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; AGED; BLOOD; CANCER STAGING; DISEASE FREE SURVIVAL; HEAD AND NECK TUMOR; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; SALVAGE THERAPY;

AGED; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; OSTEOPONTIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SALVAGE THERAPY; TUMOR MARKERS, BIOLOGICAL;

EID: 34247346481     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.06.8627     Document Type: Article

References (32)

1. Forastiere A, Koch W, Trotti A, et al: Head and neck cancer. N Engl J Med 345:1890-1900, 2001
2. Sobin LH, Hermanek P, Hutter RV: TNM classification of malignant tumors. A comparison between the new: (1987) and the old editions. Cancer 61:2310-2314, 1988
3. Senger DR, Asch BB, Smith BD, et al: A secreted phosphoprotein marker for neoplastic transformation of both epithelial and fibroblastic cells. Nature 302:714-715, 1983
4. Rittling SR, Chambers AF: Role of osteopontin in tumour progression. Br J Cancer 90:1877-1881, 2004
5. Wai PY, Kuo PC: The role of osteopontin in tumor metastasis. J Surg Res 121:228-241, 2004
6. Le QT, Sutphin PD, Raychaudhuri S, et al: Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 9:59-67, 2003
7. Zhu Y, Denhardt DT, Cao H, et al: Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer. Oncogene 24:6555-6563, 2005
8. Overgaard J, Eriksen JG, Nordsmark M, et al: Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: Results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 6:757-764, 2005
9. Cooper JS, Pajak TF, Forastiere AA, et al: Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350:1937-1944, 2004
10. Bernier J, Domenge C, Ozsahin M, et al: Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350:1945-1952, 2004
11. Kim JH, Skates SJ, Uede T, et al: Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 287:1671-1679, 2002
12. Mor G, Visintin I, Lai Y, et al: Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A 102:7677-7682, 2005
13. Koopmann J, Fedarko NS, Jain A, et al: Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 13:487-491, 2004
14. Ye B, Skates S, Mok SC, et al: Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res 12:432-441, 2006
15. Zhou Y, Dai DL, Martinka M, et al: Osteopontin expression correlates with melanoma invasion. J Invest Dermatol 124:1044-1052, 2005
16. Wai PY, Mi Z, Guo H, et al: Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis. Carcinogenesis 26:741-751, 2005
17. Tuck AB, Arsenault DM, O'Malley FP, et al: Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 18:4237-4246, 1999
18. Das R, Mahabeleshwar GH, Kundu GC: Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J Biol Chem 278:28593-28606, 2003
19. Singhal H, Bautista DS, Tonkin KS, et al: Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 3:605-611, 1997
20. Tuck AB, O'Malley FP, Singhal H, et al: Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 79:502-508, 1998
21. Ye QH, Qin LX, Forgues M, et al: Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 9:416-423, 2003
22. Fedarko NS, Jain A, Karadag A, et al: Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7:4060-4066, 2001
23. Chambers AF, Wilson SM, Kerkvliet N, et al: Osteopontin expression in lung cancer. Lung Cancer 15:311-323, 1996
24. Thalmann GN, Sikes RA, Devoll RE, et al: Osteopontin: Possible role in prostate cancer progression. Clin Cancer Res 5:2271-2277, 1999
25. Agrawal D, Chen T, Irby R, et al: Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 94:513-521, 2002
26. Pan HW, Ou YH, Peng SY, et al: Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 98:119-127, 2003
27. Ue T, Yokozaki H, Kitadai Y, et al: Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 79:127-132, 1998
28. Devoll RE, Li W, Woods KV, et al: Osteopontin (OPN) distribution in premalignant and malignant lesions of oral epithelium and expression in cell lines derived from squamous cell carcinoma of the oral cavity. J Oral Pathol Med 28:97-101, 1999
29. Celetti A, Testa D, Staibano S, et al: Overexpression of the cytokine osteopontin identifies aggressive laryngeal squamous cell carcinomas and enhances carcinoma cell proliferation and invasiveness. Clin Cancer Res 11:8019-8027, 2005
30. Ha PK, Benoit NE, Yochem R, et al: A transcriptional progression model for head and neck cancer. Clin Cancer Res 9:3058-3064, 2003
31. Muramatsu T, Shima K, Ohta K, et al: Inhibition of osteopontin expression and function in oral cancer cell lines by antisense oligonucleotides. Cancer Lett 217:87-95, 2005
32. Rischin D, Hicks RJ, Fisher R, et al: Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: A substudy of Trans-Tasman Radiation Oncology group study 98.02. J Clin Oncol 24:2098-2104, 2006